Featured Story

  • Yale scientists highlight a promising eczema study for Pfizer's Xeljanz

    Yale scientists successfully tried out Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) on a small group of people suffering from severe, treatment-resistant eczema, highlighting its added promise after the drug also demonstrated its potential in fighting two other skin conditions.

CSHL researchers report promising mouse study for Rett syndrome

Professor Nicholas Tonks and colleagues at Cold Spring Harbor Laboratory say that they've seen a promising response to PTP1B inhibitors in mouse models of Rett syndrome, an X-linked disorder that generally kills boys early in life while severely disrupting the lives of girls.

A small molecule 'exercise mimetic' may help control Type 2 diabetes and obesity

Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.

NIH successfully completes animal studies for new MERS vaccine

Zeroing in on the structure of a viral protein that Middle East respiratory syndrome (MERS) uses to enter and infect cells, a group of investigators at the NIH say they have developed a new vaccine that has proven promising in animal studies.

CRISPR/Cas9 project discovers a better method to edit T cells

CRISPR/Cas9 tech and gene editing has emerged as a hot field in biotech, spurring a full slate of startups. Now one of the pioneers in the field has supervised a project that points to a more efficient use of technology in editing T cells.

Mass General team develops a gene therapy for recurrent ovarian cancer

A research team at Massachusetts General developed a gene therapy to deliver a protein that demonstrated signs of successfully reining in recurrent ovarian cancer in a mouse model for the disease.


From Our Sister Sites


Israeli startup Eximo Medical has gained a tiny $1.6 million Series A financing to get into the clinic with its disposable catheter that combines an ablation laser with a surgical blade. The device technology, known as Cathi, is expected to improve accuracy and offer superior precision in navigating vessel blockage regardless of the type or size of lesion.  


Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.